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DrBACKGROUND The accuracy of the 2013 American College of Cardiology/American Heart Association (ACC/AHA)
Pooled Cohort Risk Equation for atherosclerotic cardiovascular disease (ASCVD) events in contemporary and ethnically
diverse populations is not well understood.
OBJECTIVES The goal of this study was to evaluate the accuracy of the 2013 ACC/AHA Pooled Cohort Risk Equation
within a large, multiethnic population in clinical care.
METHODS The target population for consideration of cholesterol-lowering therapy in a large, integrated health care
delivery system population was identiﬁed in 2008 and followed up through 2013. The main analyses excluded those with
known ASCVD, diabetes mellitus, low-density lipoprotein cholesterol levels <70 or $190 mg/dl, prior lipid-lowering
therapy use, or incomplete 5-year follow-up. Patient characteristics were obtained from electronic medical records, and
ASCVD events were ascertained by using validated algorithms for hospitalization databases and death certiﬁcates. We
compared predicted versus observed 5-year ASCVD risk, overall and according to sex and race/ethnicity. We additionally
examined predicted versus observed risk in patients with diabetes mellitus.
RESULTS Among 307,591 eligible adults without diabetes between 40 and 75 years of age, 22,283 were black, 52,917
were Asian/Paciﬁc Islander, and 18,745 were Hispanic. We observed 2,061 ASCVD events during 1,515,142 person-years.
In each 5-year predicted ASCVD risk category, observed 5-year ASCVD risk was substantially lower: 0.20% for predicted
risk <2.50%; 0.65% for predicted risk 2.50% to <3.75%; 0.90% for predicted risk 3.75% to <5.00%; and 1.85% for
predicted risk $5.00% (C statistic: 0.74). Similar ASCVD risk overestimation and poor calibration with moderate
discrimination (C statistic: 0.68 to 0.74) were observed in sex, racial/ethnic, and socioeconomic status subgroups, and in
sensitivity analyses among patients receiving statins for primary prevention. Calibration among 4,242 eligible adults with
diabetes was improved, but discrimination was worse (C statistic: 0.64).
CONCLUSIONS In a large, contemporary “real-world” population, the ACC/AHA Pooled Cohort Risk Equation sub-
stantially overestimated actual 5-year risk in adults without diabetes, overall and across sociodemographic subgroups.
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2119P ublication of the 2013 American College ofCardiology (ACC)/American Heart Association(AHA) Pooled Cohort Risk Equation for esti-
mating atherosclerotic cardiovascular disease
(ASCVD) risk is considered an important step for-
ward, as it estimates risk for both heart disease
and stroke, and provides estimates applicable to
black/African-American subjects (1,2). This equation
was developed from several prospective U.S.-based
cohorts of enrolled volunteers, primarily conducted
in the 1990s, with limited ethnic diversity and age
range. Predicted ASCVD risk using the equation
was reported to be systematically higher than the
observed risk in some highly selected cohorts (3,4)
but not in others (5). Importantly, however, these
studies included persons screened for participation
or enrolled in clinical trials, or in much earlier time
periods, with limited generalizability to contempo-
rary and diverse populations that are more represen-
tative of eligible patients treated in typical clinical
practice (6,7). Validation efforts in more contempo-
rary cohorts have further been limited due to inclu-
sion of analyzed participants treated with statin
therapy or having a high likelihood of initiating sta-
tins during follow-up (4,6,8). Lack of comprehensive
surveillance in some studies is another possible
reason for overestimation by the Pooled Cohort
Risk Equation due to under-ascertainment of ASCVD
events (3,9).SEE PAGE 2131Another major knowledge gap is the lack of accu-
rate ASCVD risk estimation speciﬁc to persons of
Asian/Paciﬁc Islander and Hispanic ethnicities, who
are currently combined with the white population in
the Pooled Cohort Risk Equation (10). Furthermore,
patterns of risk in more contemporary, community-
based populations may be signiﬁcantly different
from the older cohorts used to derive the Pooled
Cohort Risk Equation, which does not reﬂect the
recent treatment era and risk factor levels (11,12).
Estimates suggest that nearly one-half of U.S. adults
and up to 65% of European adults would be eligible
for statins on the basis of new ACC/AHA cholesterol
guidelines using the Pooled Cohort Risk Equationthrough his institution from Abbott Vascular, Inc., and Genentech. Dr. Lo h
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Manuscript received December 7, 2015; revised manuscript received Februa(13,14). Thus, evaluating the accuracy of
ASCVD risk prediction is essential if it is being
used as a decision-making tool to determine
which persons should receive statin therapy
for primary prevention (13,15), and it could
have a far-reaching impact if applied at a
population level.
To address these knowledge gaps, we
examined a very large, contemporary, multi-
ethnic, community-based “real-world” pop-
ulation whose clinical characteristics would
typically trigger a discussion of initiation of
cholesterol-lowering therapy per risk assess-
ment according to the Pooled Cohort Risk Equation
(i.e., patients 40 to 75 years of age, without known
ASCVD or diabetes, who have low-density lipoprotein
cholesterol [LDL-C] levels between 70 and 189 mg/dl).
The study compared predicted versus observed
5-year risks of ASCVD events, overall and within sex
and multiple ethnic subgroups, along with measures
of calibration and discrimination. The analyses were
repeated among a cohort of eligible adults with dia-
betes mellitus.
METHODS
SOURCE POPULATION. Kaiser Permanente Northern
California is a large integrated health care delivery
system providing comprehensive inpatient and
outpatient care to approximately 4 million ethnically
diverse persons who are highly representative of the
local and statewide population (16).
STUDY SAMPLE. Using outpatient laboratory data-
bases, we initially identiﬁed all members of the Kaiser
Permanente Northern California system between
January 1, 2008, and December 31, 2008, who were
$21 years of age and had LDL-C levels between 70 and
189 mg/dl within 5 years before study entry. The
earliest LDL-C measurement in the year 2008
was used as the index date or, if the patient’s last
available LDL-C measurement was before 2008, the
index date used was January 1, 2008. We excluded
those who met any of the following criteria: sex
or race/ethnicity was unknown; prescribed statins or
other lipid-lowering therapies within 5 years beforeas received a research grant through her institution
stitution from Abbott Diagnostic, Amarin, Amgen,
ron, Roche Diagnostic, Sanoﬁ-Synthélabo, Takeda
rican Heart Association, and the American Diabetes
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2120the index date; previous hospitalization for acute
myocardial infarction, ischemic stroke, or receipt
of coronary artery bypass surgery or percutaneous
coronary intervention, identiﬁed from health plan
hospital discharge or billing claims databases using
previously validated methods (17,18); <12 months of
continuous membership and pharmacy beneﬁt before
the index date (to ensure more complete information
on clinical characteristics); and <5 years of complete
follow-up, except if due to death. On the basis of
the requirements of the ASCVD risk calculator, pa-
tients with missing systolic blood pressure, total
cholesterol, or high-density lipoprotein cholesterol
(HDL-C) information were also excluded. We further
excluded patients who received statins during
follow-up if used for primary prevention of ASCVD
(i.e., statin initiated before a documented ASCVD
event) on the basis of ﬁlled dispensings found in
pharmacy databases. The cohort was then stratiﬁed
according to diabetes mellitus status at the index date
on the basis of data from a validated regional diabetes
registry (19,20).
PREDICTION OF ASCVD RISK. The 10-year ASCVD
predicted risk score was calculated for cohort mem-
bers between 40 and 75 years of age, as per the
guideline-recommended ASCVD prevention age
group (1,13). To directly compare observed versus
predicted ASCVD risk at 5-year follow-up, we annu-
alized the 10-year predicted ASCVD risk and catego-
rized the population into 4 groups of estimated 5-year
risk (<2.50%; from 2.50% to <3.75%; from 3.75%
to <5.00%; and $5.00%), as was previously used (8).
ASCERTAINMENT OF ASCVD EVENTS. Follow-up
occurred through December 31, 2013. ASCVD events
were deﬁned as acute myocardial infarction, coronary
heart disease (CHD) death, or fatal or nonfatal
ischemic stroke. Myocardial infarction and ischemic
stroke were identiﬁed from comprehensive health
plan hospital discharge or billing claims databases on
the basis of previously validated algorithms (17,18,21)
using International Classiﬁcation of Diseases-Ninth
Revision, primary discharge codes. Coronary death
was determined on the basis of International Classi-
ﬁcation of Diseases-10th Revision, codes (I11, I20–I25)
(22) obtained from state death certiﬁcate ﬁles through
2013, which was the latest available information at
the time of analysis.
COVARIATES. Comorbidity was characterized during
a 5-year period before the index date on the
basis of relevant International Classiﬁcation of
Diseases-Ninth Revision, diagnosis and procedure
codes (21,23) from health plan electronic medical re-
cords and a regional diabetes registry (19,20).Baseline data were collected from electronic medical
records on age, sex, self-reported race/ethnicity,
cigarette smoking status, and body mass index.
Ambulatory measures of baseline total cholesterol,
HDL-C, LDL-C, systolic blood pressure, and use of
antihypertensive medication within 5 years before
the index date were ascertained from comprehensive
health plan laboratory, outpatient visit, and phar-
macy databases.
ANALYTIC APPROACH. Analyses were conducted
by using SAS version 9.3 (SAS Institute, Inc.,
Cary, North Carolina). Baseline characteristics were
compared across predicted ASCVD risk categories by
using analysis of variance for continuous variables
and chi-squared tests for categorical variables. We
calculated the 5-year incidence of ASCVD events
with 95% conﬁdence limits by using the ﬁrst hos-
pitalized acute myocardial infarction, ﬁrst hospital-
ized ischemic stroke, or coronary death observed
during follow-up. The 5-year expected incidence of
ASCVD risk was calculated on the basis of the mean
ASCVD predicted risk and associated 95% conﬁdence
interval (CI) among patients whose predicted risk
fell within each risk category. We then examined
the observed and expected 5-year incidence of
ASCVD events among nondiabetic patients between
40 and 75 years of age, overall and stratiﬁed ac-
cording to sex, race/ethnicity (non-Hispanic white,
non-Hispanic black, Asian/Paciﬁc Islander, and His-
panic) and measures of socioeconomic status by
using U.S. Census–based residential block–level data
(18). The observed and expected 5-year ASCVD
incidence rates were also separately examined among
eligible patients with diabetes between 40 and 75 years
of age.
Accuracy was assessed by evaluating calibration
and discrimination. Following the approach used by
Cook and Ridker (11), calibration plots were generated
comparing observed versus expected risk of ASCVD
events within each estimated risk category. Discrim-
ination was assessed by using the C statistic from a
logistic regression model evaluating predicted risk
categories with observed 5-year ASCVD event risks.
Finally, as a sensitivity analysis, the accuracy of the
risk equation was examined among eligible adults
with and without diabetes who received statin ther-
apy for primary prevention during the follow-up
period.
RESULTS
STUDY COHORT AND BASELINE CHARACTERISTICS. A
total of 307,591 eligible adults aged 40 to 75 years
were identiﬁed who did not have diabetes, prior
FIGURE 1 Cohort Assembly
Adults with LDL between 70 mg/dL and 189 mg/dL
and no prior lipid-lowering therapy or known ASCVD
N=941,516
Additional exclusions (not mutually exclusive):
<12 months continuous membership (N = 100,584)
<12 months continuous pharmacy benefit (N = 155,094)
<5-year complete follow-up (N = 302,476)
Age <40 or >75 years old (N = 160,359)
Statin used for primary prevention during follow-up (N = 85,808)
No ambulatory systolic blood pressure (N = 63,038)
Missing total cholesterol (N = 3,347)
Missing HDL cholesterol (N = 5,753)
Other lipid-lowering therapy used (N = 12,546)
Final Eligible Cohort
N = 311,833
40-75 Years Old
Without Diabetes Mellitus
N = 307,591
40-75 Years Old
With Diabetes Mellitus
N = 4,242
Between January 1, 2008, and December 31, 2008, a cohort of eligible adults, 40 to 75 years of age, with or without diabetes mellitus was identiﬁed.
ASCVD ¼ atherosclerotic cardiovascular disease; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein.
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2121ASCVD, or earlier receipt of lipid-lowering therapy
and who had complete 5-year follow-up (Figure 1).
In addition, 4,242 patients with diabetes were sepa-
rately identiﬁed who did not have known ASCVD,
prior lipid-lowering therapy, or any other exclusion
criteria.
Among eligible adults without diabetes, their mean
age was 54.8 years, and 61.6% were women; 22,283
were black/African American, 52,917 were Asian/
Paciﬁc Islander, and 18,745 were Hispanic. Nearly
one-third were former or current smokers, 28% were
obese, and 33% were taking medication for hyper-
tension (Table 1).
Fifty-seven percent of patients were in the lowest
(<5%) category of 10-year predicted ASCVD risk, with
12% having predicted risk 5.0% to <7.5%, 8% having
predicted risk 7.5% to <10%, and the remaining 23%
having predicted risk $10% (Table 1). Patients with
higher predicted ASCVD risk were more likely to be
older and male, be former or current smokers, and
have higher systolic blood pressure and body mass
index, lower HDL-C, and higher LDL-C.
ACCURACY OF ASCVD RISK EQUATION ACCORDING
TO DIABETES STATUS. Among eligible patients 40to 75 years of age without diabetes, 2,061 ASCVD
events were observed during 1,515,142 person-years,
with 1,464 (0.5%) acute myocardial infarctions, 525
(0.2%) CHD-related deaths, and 71 (0.02%) ischemic
strokes. The cumulative risk of ASCVD events was
linear during the entire 5-year follow-up period
(Figure 2). Observed 5-year ASCVD incidence was
substantially lower than the predicted risk in each
category: 0.20% (95% CI: 0.20 to 0.25) for predicted
risk <2.50%; 0.65% (95% CI: 0.55 to 0.70) for pre-
dicted risk 2.50% to <3.75%; 0.90% (95% CI: 0.75 to
1.00) for predicted risk 3.75% to <5.00%; and 1.85%
(95% CI: 1.75 to 1.95) for predicted risk $5.00%
(Central Illustration). Calibration between the pre-
dicted versus observed 5-year ASCVD incidence was
poor (Figure 3) and the discrimination was moderate
(C statistic: 0.74).
Among eligible 40- to 75-year-olds with diabetes,
148 events were observed during 19,196 person-
years, with 84 (2%) acute myocardial infarctions, 54
(1.3%) CHD-related deaths, and 10 (0.2%) ischemic
strokes. Observed 5-year ASCVD incidence in each
predicted risk category was as follows: 0.10%
(95% CI: 0% to 0.85%) for predicted risk <2.50%;
TABLE 1 Baseline Characteristics of the Adults 40 to 75 Years of Age With and Without Diabetes Mellitus, Stratiﬁed According to Predicted
ASCVD Risk Category
10-Year Predicted Risk of ASCVD Events
p Value
Overall
(N ¼ 307,591)
<5%
(n ¼ 175,605)
5% to <7.50%
(n ¼ 36,896)
7.50% to <10%
(n ¼ 25,142)
$10%
(n ¼ 69,948)
No diabetes mellitus
10-yr predicted risk of ASCVD
Mean  SD 6.60  7.02 2.08  1.33 6.16  0.72 8.68  0.72 17.43  6.42 <0.001
Median (IQR) 3.94 (1.56–9.22) 1.81 (0.92–3.08) 6.12 (5.54–6.76) 8.64 (8.05–9.29) 15.70 (12.37–20.88) <0.001
Range 0.04–65.64 0.04–5.00 5.00–7.50 7.50–10.00 10.00–65.64
Age, yrs 54.8  9.1 49.8  6.1 56.1  6.8 58.6  7.0 65.1  7.2 <0.001
Female 189,511 (61.6) 134,990 (76.9) 18,745 (50.8) 11,207 (44.6) 24,569 (35.1) <0.001
Race/ethnicity <0.001
White/European
(non-Hispanic)
212,039 (68.9) 115,652 (65.9) 26,303 (71.3) 18,067 (71.9) 52,017 (74.4)
Black/African American
(non-Hispanic)
22,283 (7.2) 10,164 (5.8) 3,414 (9.3) 2,427 (9.7) 6,278 (9.0)
Asian/Paciﬁc Islander 52,917 (17.2) 36,831 (21.0) 5,099 (13.8) 3,296 (13.1) 7,691 (11.0)
Hispanic 18,745 (6.1) 12,035 (6.9) 1,875 (5.1) 1,222 (4.9) 3,613 (5.2)
Other/unknown 1,607 (0.5) 923 (0.5) 205 (0.6) 130 (0.5) 349 (0.5)
Residential block-level
socioeconomic status
Median household income <0.001
$$35,000 295,497 (96.1) 169,441 (96.5) 35,360 (95.8) 23,984 (95.4) 66,712 (95.4)
<$35,000 11,772 (3.8) 6,004 (3.4) 1,493 (4.0) 1,118 (4.4) 3,157 (4.5)
Missing 322 (0.1) 160 (0.1) 43 (0.1) 40 (0.2) 79 (0.1)
Highest level of education <0.001
High school graduate or higher 275,867 (89.7) 157,925 (89.9) 33,073 (89.6) 22,461 (89.3) 62,408 (89.2)
Less than high school 31,409 (10.2) 17,524 (10.0) 3,781 (10.2) 2,641 (10.5) 7,463 (10.7)
Missing 315 (0.1) 156 (0.1) 42 (0.1) 40 (0.2) 77 (0.1)
Tobacco use <0.001
Current 29,537 (9.6) 10,022 (5.7) 5134 (13.9) 3,929 (15.6) 10,452 (14.9)
Former 67,611 (22.0) 19,316 (11.0) 9,762 (26.5) 7,964 (31.7) 30,569 (43.7)
Never 210,443 (68.4) 146,267 (83.3) 22,000 (59.6) 13,249 (52.7) 28,927 (41.4)
Systolic blood pressure, mm Hg 124.5  15.0 120.2  13.8 126.7  13.5 128.2  13.8 132.8  15.1 <0.001
BMI, kg/m2 <0.001
<18.5 3,604 (1.2) 2,249 (1.3) 337 (0.9) 235 (0.9) 783 (1.1)
18.5–24.9 107,422 (34.9) 70,931 (40.4) 10,530 (28.5) 6,978 (27.8) 18,983 (27.1)
25.0–29.9 109,104 (35.5) 57,729 (32.9) 13,773 (37.3) 9,544 (38.0) 28,058 (40.1)
30.0–39.9 76,401 (24.8) 38,655 (22.0) 10,645 (28.9) 7,325 (29.1) 19,776 (28.3)
$40 8,620 (2.8) 4,845 (2.8) 1,272 (3.4) 846 (3.4) 1,657 (2.4)
Missing 2,440 (0.8) 1,196 (0.7) 339 (0.9) 214 (0.9) 691 (1.0)
Antihypertensive
medication use
101,089 (32.9) 34,085 (19.4) 13,447 (36.4) 10,733 (42.7) 42,824 (61.2) <0.001
Lipoproteins, mg/dl
Total 197.5  29.7 194.6  29.0 201.7  29.7 202.0  30.1 201.0  30.5 <0.001
HDL-C 55.6  15.4 58.0  15.1 53.4  15.1 52.8  15.2 51.7  15.4 <0.001
LDL-C 118.1  24.4 115.2  23.9 122.4  24.4 122.6  24.7 121.7  24.4 <0.001
Continued on the next page
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21222.55% (95% CI: 1.35% to 4.95%) for predicted risk
2.50% to <3.75%; 2.65% (95% CI: 1.30% to 5.30%) for
predicted risk 3.75% to <5.00%; and 5.50% (95% CI:
4.60% to 6.50%) for predicted risk $5.00% (Central
Illustration). Calibration was fair between predicted
versus observed 5-year risk of ASCVD events, and
discrimination was only modest (C statistic: 0.64)
(Figure 3).ACCURACY OF ASCVD RISK EQUATION ACCORDING TO
SEX, RACE/ETHNICITY, AND SOCIOECONOMIC STATUS.
Among both nondiabetic men and women, there was
systematic overestimation of observed 5-year ASCVD
incidence in each predicted risk category, with simi-
larly poor calibration in both sexes (Figures 3 and 4).
Discrimination in nondiabetic women (C statistic:
0.72) was better than in men (C statistic: 0.68).
TABLE 1 Continued
10-year Predicted Risk of ASCVD Events
p Value
Overall
(N ¼ 4,242)
<5.00%
(n ¼ 834)
5.00% to <7.50%
(n ¼ 369)
7.50% to <10%
(n ¼ 327)
$10%
(n ¼ 2,712)
Diabetes mellitus
10-year predicted risk of ASCVD
Mean  SD 26.81  26.19 2.05  1.39 6.19  0.72 8.72  0.71 40.23  24.33 <0.001
Median (IQR) 17.36 (5.12–42.58) 1.82 (0.82–3.11) 6.13 (5.56–6.79) 8.67 (8.12–9.32) 34.49 (19.24–57.03) <0.001
Range 0.00–100.00 0.00–5.00 5.01–7.49 7.51–9.99 10.01–100.00
Age, yrs 58.1  9.6 47.6  5.1 51.7  6.1 54.0  6.3 62.7  8.0 <0.001
Female 2,127 (50.1) 663 (79.5) 229 (62.1) 209 (63.9) 1,026 (37.8) <0.001
Race/ethnicity <0.001
White/European
(non-Hispanic)
2,371 (55.9) 390 (46.8) 221 (59.9) 184 (56.3) 1,576 (58.1)
Black/African American
(non-Hispanic)
544 (12.8) 55 (6.6) 32 (8.7) 36 (11.0) 421 (15.5)
Asian/Paciﬁc Islander 768 (18.1) 253 (30.3) 77 (20.9) 62 (19.0) 376 (13.9)
Hispanic 529 (12.5) 127 (15.2) 37 (10.0) 42 (12.8) 323 (11.9)
Other/unknown 30 (0.7) 9 (1.1) 2 (0.5) 3 (0.9) 16 (0.6)
Residential block-level
socioeconomic status
Median household income 0.57
$$35,000 3,971 (93.6) 791 (94.8) 349 (94.6) 306 (93.6) 2,525 (93.1)
<$35,000 268 (6.3) 42 (5.0) 20 (5.4) 21 (6.4) 185 (6.8)
Missing 3 (0.1) 1 (0.1) 0 0 2 (0.1)
Highest level of education 0.76
High school graduate or higher 3,534 (83.3) 705 (84.5) 311 (84.3) 275 (84.1) 2,243 (82.7)
Less than high school 706 (16.6) 128 (15.3) 58 (15.7) 52 (15.9) 468 (17.3)
Missing 2 (0.0) 1 (0.1) 0 0 1 (0.0)
Tobacco use <0.001
Current 481 (11.3) 29 (3.5) 31 (8.4) 46 (14.1) 375 (13.8)
Former 1,227 (28.9) 28 (3.4) 49 (13.3) 69 (21.1) 1,081 (39.9)
Never 2,534 (59.7) 777 (93.2) 289 (78.3) 212 (64.8) 1,256 (46.3)
Systolic blood pressure, mm Hg 129.5  16.6 122.3  13.7 126.9  15.5 128.5  15.0 1,32.3  16.9 <0.001
BMI, kg/m2 <0.001
<18.5 50 (1.2) 12 (1.4) 2 (0.5) 2 (0.6) 34 (1.3)
18.5–24.9 716 (16.9) 183 (21.9) 55 (14.9) 42 (12.8) 436 (16.1)
25.0–29.9 1,137 (26.8) 208 (24.9) 84 (22.8) 88 (26.9) 757 (27.9)
30.0–39.9 1,924 (45.4) 325 (39.0) 191 (51.8) 161 (49.2) 1,247 (46.0)
$40 389 (9.2) 102 (12.2) 36 (9.8) 32 (9.8) 219 (8.1)
Missing 26 (0.6) 4 (0.5) 1 (0.3) 2 (0.6) 19 (0.7)
Antihypertensive medication use 2,924 (68.9) 410 (49.2) 199 (53.9) 191 (58.4) 2,124 (78.3) <0.001
Lipoproteins, mg/dl
Total 175.9  31.1 174.9  27.7 178.7  30.0 180.5  33.6 175.3  31.8 <0.01
HDL-C 47.9  13.9 53.7  14.4 48.6  13.9 49.5  14.5 45.8  13.1 <0.001
LDL-C 99.7  23.4 97.8  20.9 101.3  23.5 101.9  25.6 99.7  23.8 <0.05
Values are mean  SD or n (%), unless otherwise indicated.
ASCVD ¼ atherosclerotic cardiovascular disease; BMI ¼ body mass index; HDL-C ¼ high-density lipoprotein cholesterol; IQR ¼ interquartile range; LDL-C ¼ low-density
lipoprotein cholesterol.
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subjects are considered under “white or other” in the
ASCVD risk equation, we compared the observed
versus predicted 5-year ASCVD incidence separately
among non-Hispanic white, non-Hispanic black,
Asian/Paciﬁc Islander, and Hispanic subjects. Wefound systematic overestimation of actual ASCVD risk
in each of these ethnic groups (Figure 4) and similarly
poor calibration, but discrimination varied in each
group (C statistic: 0.70 to 0.74) (Figure 3). Results
were also similar across measures of socioeconomic
status.
FIGURE 2 Cumulative Risk of ASCVD Events During 5-Year Follow-Up Off Statin
Therapy
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N represents the cumulative number of events observed during each follow-up period
for calculating the cumulative risk of atherosclerotic cardiovascular disease (ASCVD)
events per year of follow-up among all eligible adults 40 to 75 years of age who did
not have diabetes and did not receive statin therapy for primary prevention of
ASCVD.
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PERSONS TREATED WITH STATINS FOR PRIMARY
PREVENTION. In sensitivity analyses, eligible adults
who did or did not have diabetes but received statin
therapy for primary prevention during follow-up
were separately examined. In eligible adults without
diabetes, there was overestimation of actual 5-year
ASCVD incidence in each predicted risk category
(Online Figure A). Observed rates for this population
were approximately 6 times lower than predicted. In
contrast to ﬁndings in untreated eligible patients
with diabetes, there was a systematic overestimation
of the observed 5-year ASCVD incidence in each
predicted risk category among eligible adults
with diabetes who received statin therapy for primary
prevention. Calibration was poor and discrimination
was modest in both those with (C statistic: 0.61)
and without (C statistic: 0.68) diabetes who received
statin therapy for primary prevention (Online
Figure B).
DISCUSSION
In a large, contemporary, “real-world” cohort with
broad racial/ethnic diversity, we showed that the
ACC/AHA Pooled Cohort Risk Equation substantiallyoverestimated actual 5-year ASCVD risk in each
predicted risk category within eligible adults without
diabetes (40 to 75 years of age with no known ASCVD
and with LDL-C levels 70 to 189 mg/dl) who are a
recommended target population for consideration
of cholesterol-lowering therapy. Importantly, this
overestimation was similar in both men and women,
as well as in 4 major ethnic groups, with poor cali-
bration in each subgroup. Discrimination, as
measured according to the C statistic, was fair to
moderate, depending on the patient group. Of
interest, we found better calibration among eligible
adults age 40 to 75 years with diabetes but worse
discrimination.
Since release of the 2013 ACC/AHA cholesterol
treatment guidelines, there has been an ongoing
debate, especially regarding application of the new
Pooled Cohort Risk Equation for assessing ASCVD risk
within and outside the United States. In selected U.S.-
based prospective cohorts not used to derive the
Pooled Cohort Risk Equation, such as the MESA
(Multi-Ethnic Study of Atherosclerosis) and the
REGARDS (Reasons for Geographic and Racial Differ-
ences in Stroke) studies, the estimated ASCVD risk
was higher than observed risk (3,4). Similarly, in a
European population $55 years of age, the risk
equation had poor calibration (15). It has been pro-
posed that results of these and related evaluation
efforts are limited due to approximately 25% of par-
ticipants taking statins or having a high likelihood of
initiating statin therapy during follow-up (6,8).
Under-ascertainment of ASCVD events in these
studies has also been suggested as a possible reason
for observed overestimation of risk (3,9). There is also
concern as to how well the risk equation works in
more contemporary patients compared with the older
cohorts used to derive the equation (3,11,12). Analyses
from the Women’s Health Study estimated hypo-
thetical rates if no women were prescribed statins or
underwent revascularization and suggested that after
accounting for intervention effects of statins and
revascularization, as well as hypothetical confound-
ing by indication or under-ascertainment of events,
discrepancy would still occur in the observed versus
predicted ASCVD risk (11). However, because the
Women’s Health Study enrolled primarily white fe-
male nurses between 1992 and 1995, the results are
not necessarily generalizable to more diverse,
contemporary populations. Similarly, recent analyses
from the MESA study share the important limitation
of lack of generalizability, as research participants are
not likely to accurately represent the general popu-
lation in clinical practice and during a recent treat-
ment era (4).
CENTRAL ILLUSTRATION Cardiovascular Risk Prediction in Clinical Care: Comparison of Observed
Versus Expected ASCVD Risks
Rana, J.S. et al. J Am Coll Cardiol. 2016;67(18):2118–30.
Observed 5-year risks of atherosclerotic cardiovascular disease (ASCVD) events within each predicted risk category in eligible adults
40 to 75 years of age are shown stratiﬁed according to diabetes status.
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FIGURE 3 Calibration and Discrimination of ASCVD Risk Equation
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Calibration plots and model-based discrimination estimates (C statistic) comparing observed 5-year risk of atherosclerotic cardiovascular disease (ASCVD)
events in each predicted risk category in eligible adults 40 to 75 years of age are shown according to diabetes status and in nondiabetic sex, racial/ethnic,
and socioeconomic subgroups.
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FIGURE 4 Comparison of Observed Versus Expected ASCVD Risks in Subgroups
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Observed 5-year risks of atherosclerotic cardiovascular disease (ASCVD) events within each predicted risk category in eligible nondiabetic adults 40 to 75
years of age are shown within sex, racial/ethnic, and socioeconomic status subgroups.
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First, we evaluated the accuracy of the Pooled Cohort
Risk Equation in the most contemporary cohort
studied to date, with study entry in 2008 andcomplete follow-up through 2013. Second, we
excluded patients who had received any statin ther-
apy during the 5 years before or anytime during
follow-up, thus minimizing any confounding from
Rana et al. J A C C V O L . 6 7 , N O . 1 8 , 2 0 1 6
Cardiovascular Risk Prediction in Clinical Care M A Y 1 0 , 2 0 1 6 : 2 1 1 8 – 3 0
2128statin use when evaluating performance of the risk
calculator. Third, because we studied patients
receiving care within an integrated health care de-
livery system, we had complete ascertainment of
ASCVD events. Fourth, even after restricting the
analysis to the target population of nondiabetic
adults, 40 to 75 years of age, who had LDL-C levels
between 70 and 189 mg/dl and no known ASCVD, we
studied a very large population of 307,591 men and
women. This population is notably larger and more
representative than any previous studies (e.g., 3,433
adults $55 years of age, including patients with dia-
betes, in the Rotterdam Study [15] and 10,997 from
the REGARDS study with a selected subset of 3,333
participants $65 years of age linked to Medicare
claims data [8]). Fifth, we examined 4 major racial/
ethnic groups, including Asian/Paciﬁc Islander and
Hispanic subjects, which constitute a major propor-
tion of the U.S. population (24). Present guidelines (1)
caution against applying this algorithm to groups
that are neither white nor black/African American,
and we further demonstrated that the Pooled
Cohort Risk Equation overestimated actual ASCVD
risk across all 4 ethnic groups in our study population
with variable discrimination. Finally, in contrast
to previous cholesterol treatment guidelines (25), the
Pooled Cohort Risk Equation includes diabetes as
part of the scoring criteria, rather than considering it
a CHD-equivalent, and a recent study found impor-
tant differences in predicted risk among those
with diabetes (26). We found that calibration was
improved, but discrimination was poorer, for
untreated eligible adults with diabetes; importantly,
there was a wide range of ASCVD risk in these
patients, which could inform future studies evalu-
ating different thresholds for initiating statin therapy
in patients with diabetes.
STUDY LIMITATIONS. First, we used 5-year versus
10-year follow-up, and it is possible that incidence
rates in the ﬁrst 5 years of follow-up could be less
than in the subsequent 5 years. However, we
observed a cumulative risk of ASCVD that was linear
during the 5-year follow-up (Figure 2), which directly
supports extrapolation of our results to 10-year risk.
Studying 5-year risk also allowed for a contemporary
estimate of ASCVD risk. Risk score overestimation
may have been due to exclusion of those who were
started on statins; however, in a sensitivity analysis,
there was poor calibration and suboptimal discrimi-
nation of the Pooled Cohort Risk Equation in eligible
patients, with or without diabetes, treated with sta-
tins for primary prevention during follow-up (Online
Figures A and B). Inclusion of death certiﬁcate data
to help deﬁne fatal CHD may have led to somemisclassiﬁcation. Our study population may not be
fully generalizable to all parts of the United States or
to patients treated in different health care delivery
systems; however, approximately one-third of the
sample was obese, had known hypertension, and was
a current or former smoker. In addition, unlike pre-
vious studies, we had a very ethnically diverse sam-
ple of patients with uniform access to care, as well as
comprehensive ascertainment of clinically recognized
ASCVD events, which argues for greater generaliz-
ability and validity. Given that most adults with dia-
betes within our health system were receiving statins
for primary prevention, and were therefore not
eligible for analysis, the sample we examined is not
necessarily fully representative of all patients with
diabetes. However, our study sample allowed
comprehensive assessment of the observed 5-year
ASCVD risk among adults with clinically recognized
diabetes across the range of predicted risk, and we
required all patients to have the full 5-year follow-up,
which is critical to allow enough time to identify all
fatal and nonfatal ASCVD events. We are unaware of
any evidence that patients with symptoms or signs of
possible ASCVD are more or less likely to remain
insured and stay or leave our health system. There is
a possibility that including those who died, but not
those censored from disenrollment, could artiﬁcially
raise the observed event rates, but given that the
absolute risk of death was very low in this population,
it is highly unlikely to have had a substantive impact
on the results.
Insured patients may have better health habits
than patients who are not able to afford insurance or
choose not to obtain it. However, if one considers the
rationale for risk assessment in the ACC/AHA guide-
line, this real-world population is more likely to
represent typical patients in U.S. communities who
are seeing a health care provider and who may be
considered for preventive therapies, compared with
volunteers enrolled into prospective cohort studies or
interventional clinical trials. Furthermore, if signiﬁ-
cant variation exists in regional population charac-
teristics or outcomes, and if there are systematic
differences in cardiovascular risk reduction efforts
across health care settings, it is critical that health
care providers use a risk assessment tool that is cali-
brated to the patient population being seen by those
providers.
CONCLUSIONS
As recently recommended (27), we conducted a crit-
ical evaluation of the ASCVD Pooled Cohort Risk
Equation from a relevant large, diverse, real-world
PERSPECTIVES
COMPETENCY IN SYSTEMS-BASED PRACTICE: The 2013
ACC/AHA Pooled Cohort Risk Equation estimates risk for both
coronary events and stroke. However, the risk equation sub-
stantially overestimates ASCVD risk in adults without diabetes
mellitus and has suboptimal accuracy across sociodemographic
subgroups as well as in adults with diabetes who do not receive
statin therapy for primary prevention.
TRANSLATIONAL OUTLOOK: More research is needed to
develop risk assessment tools that are calibrated to diverse,
contemporary populations, especially given the implications of
recommending lifelong statin therapy.
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2129target population, overall and in key understudied
subgroups. We found that this risk equation sub-
stantially overestimated actual ASCVD risk in
adults not treated with statin therapy for primary
prevention without diabetes (overall and across all
sociodemographic subgroups), and demonstrated
suboptimal accuracy in those with or without dia-
betes. Our study provides evidence to support reca-
libration of the ASCVD Pooled Cohort Risk Equation
in adults without diabetes, especially given the
individual and public health implications of wide-
spread application of this risk calculator. Ongoing
research and dialogue in this area remains crucial
and should be encouraged to provide more rigorous,
valid evidence in contemporary, diverse populations
(26–28).
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